155 related articles for article (PubMed ID: 33841635)
21. PD-L1 and miR-34a are Prognostic Factors for Primary Gastric Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP.
Wang J; Shang S; Li J; Deng H; Ouyang L; Xie H; Zhu H; Li Y; Zuo C
Cancer Manag Res; 2020; 12():4999-5008. PubMed ID: 32612387
[TBL] [Abstract][Full Text] [Related]
22. MALAT-1: Immunomodulatory lncRNA hampering the innate and the adaptive immune arms in triple negative breast cancer.
Mekky RY; Ragab MF; Manie T; Attia AA; Youness RA
Transl Oncol; 2023 May; 31():101653. PubMed ID: 36907052
[TBL] [Abstract][Full Text] [Related]
23. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
24. Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1.
Tian W; Sun Y; Cheng Y; Ma X; Du W; Shi W; Guo Q
Thorac Cancer; 2021 Oct; 12(19):2551-2563. PubMed ID: 34469060
[TBL] [Abstract][Full Text] [Related]
25. Cationic versus neutral microbubbles for ultrasound-mediated gene delivery in cancer.
Wang DS; Panje C; Pysz MA; Paulmurugan R; Rosenberg J; Gambhir SS; Schneider M; Willmann JK
Radiology; 2012 Sep; 264(3):721-32. PubMed ID: 22723497
[TBL] [Abstract][Full Text] [Related]
26. MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells.
Zuo Y; Zheng W; Liu J; Tang Q; Wang SS; Yang XS
Neoplasma; 2020 Jan; 67(1):93-101. PubMed ID: 31777260
[TBL] [Abstract][Full Text] [Related]
27. miR-34a Enhances the Susceptibility of Gastric Cancer to Platycodin D by Targeting Survivin.
Peng Y; Fan JY; Xiong J; Lou Y; Zhu Y
Pathobiology; 2019; 86(5-6):296-305. PubMed ID: 31711057
[TBL] [Abstract][Full Text] [Related]
28. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of Lnc-OC1 Induced Cell Apoptosis and Decreased Cell Viability by Releasing miR-34a and Inhibiting PD-L1 in Endometrial Carcinoma.
Liu Y; Chang Y; Cai YX
Reprod Sci; 2020 Oct; 27(10):1848-1856. PubMed ID: 32748220
[TBL] [Abstract][Full Text] [Related]
30. Ultrasound-Targeted Microbubble Destruction Enhances the Inhibitive Efficacy of miR-21 Silencing in HeLa Cells.
Zhao S; Xie J; Zhao C; Cao W; Yu Y
Med Sci Monit; 2021 Feb; 27():e923660. PubMed ID: 33606670
[TBL] [Abstract][Full Text] [Related]
31. Tumor-derived exosomes encapsulating miR-34a promote apoptosis and inhibit migration and tumor progression of colorectal cancer cells under in vitro condition.
Hosseini M; Baghaei K; Amani D; Ebtekar M
Daru; 2021 Dec; 29(2):267-278. PubMed ID: 34405380
[TBL] [Abstract][Full Text] [Related]
32. 5-Aminolevulinic acid-mediated sonodynamic therapy induces anti-tumor effects in malignant melanoma via p53-miR-34a-Sirt1 axis.
Hu Z; Fan H; Lv G; Zhou Q; Yang B; Zheng J; Cao W
J Dermatol Sci; 2015 Aug; 79(2):155-62. PubMed ID: 25982144
[TBL] [Abstract][Full Text] [Related]
33. Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma.
Wang Y; Zhang X; Xu C; Nan Y; Fan J; Zeng X; Kwon BS; Ju D
Front Immunol; 2022; 13():1004475. PubMed ID: 36544785
[TBL] [Abstract][Full Text] [Related]
34. High-intensity focused ultrasound combined with herpes simplex virus thymidine kinase gene-loaded ultrasound-targeted microbubbles improved the survival of rabbits with VX₂ liver tumor.
Zhou SJ; Li SW; Wang JJ; Liu ZJ; Yin GB; Gong JP; Liu CA
J Gene Med; 2012; 14(9-10):570-9. PubMed ID: 22941868
[TBL] [Abstract][Full Text] [Related]
35. Isorhamnetin and anti-PD-L1 antibody dual-functional mesoporous silica nanoparticles improve tumor immune microenvironment and inhibit YY1-mediated tumor progression.
Liu H; Han J; Lv Y; Zhao Z; Zheng S; Sun Y; Sun T
J Nanobiotechnology; 2023 Jul; 21(1):208. PubMed ID: 37408047
[TBL] [Abstract][Full Text] [Related]
36. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
Shadbad MA; Safaei S; Brunetti O; Derakhshani A; Lotfinejad P; Mokhtarzadeh A; Hemmat N; Racanelli V; Solimando AG; Argentiero A; Silvestris N; Baradaran B
Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440380
[TBL] [Abstract][Full Text] [Related]
37. Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer.
Gong X; Li X; Jiang T; Xie H; Zhu Z; Zhou F; Zhou C
J Thorac Oncol; 2017 Jul; 12(7):1085-1097. PubMed ID: 28478231
[TBL] [Abstract][Full Text] [Related]
38. Exosomes-Coated miR-34a Displays Potent Antitumor Activity in Pancreatic Cancer Both in vitro and in vivo.
Zuo L; Tao H; Xu H; Li C; Qiao G; Guo M; Cao S; Liu M; Lin X
Drug Des Devel Ther; 2020; 14():3495-3507. PubMed ID: 32921986
[TBL] [Abstract][Full Text] [Related]
39. Oncolytic vaccinia virus acts synergistically with anti-PD-L1 antibody to enhance the killing of colon cancer cells by CD8
Wu R; Tong S; Yin J; Zhu Z; Mao Z; Xu L
Pathol Res Pract; 2023 Jul; 247():154535. PubMed ID: 37257241
[TBL] [Abstract][Full Text] [Related]
40. Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway.
Li X; Wang S; Mu W; Barry J; Han A; Carpenter RL; Jiang BH; Peiper SC; Mahoney MG; Aplin AE; Ren H; He J
J Exp Clin Cancer Res; 2022 Jan; 41(1):41. PubMed ID: 35086548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
